In this era of precision medicine, with the help of biomarkers, immunotherapy has
significantly improved prognosis of many patients with malignant tumor. Deficient mismatch …

Intratumour heterogeneity (ITH) is pervasive across all cancers studied and may provide the
evolving tumour multiple routes to escape immune surveillance. Immune checkpoint …

Clinical studies combining radiation and immunotherapy have shown promising response
rates, strengthening efforts to sensitize tumors to immune-mediated attack. Thus, there is an …

Anti‐programmed cell death 1 (anti‐PD‐1) therapy shows definite but modest activity in
patients with advanced/metastatic head and neck squamous cell carcinoma (HNSCC) …

Assessment of T-cell response to the tumor is important for diagnosis of the disease and
monitoring of therapeutic efficacy. For this, new non-destructive label-free methods are …

The current understanding of humoral immune response in cancer patients suggests that
tumors may be infiltrated with diffuse B cells of extra-tumoral origin or may develop …

Carcinogenesis in the process of long-term co-evolution of tumor cells and immune
environment essentially becomes possible due to incorrect decisions made, remembered …

Immune checkpoint inhibitors (ICIs) have been used for the treatment of various types of
cancers, including malignant melanoma. Mechanistic exploration of tumor immune …

Temporal analysis of the T cell receptor (TCR) repertoire has been used to monitor treatment-
induced changes in antigen-specific T cells in patients with cancer. However, the lack of …

Background: Some peptide anticancer vaccines elicit a strong T-cell memory response but
fail to suppress tumor growth. To gain insight into tumor resistance, we compared two …